Fulgent Genetics, Inc. (FLGT) News
Follow Fulgent Genetics, Inc. (FLGT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Fulgent Genetics Reports Q3 2026 Results, Revenue Up 8%
Fulgent Genetics said third-quarter 2026 revenue grew 8% year over year and losses narrowed. It also improved its full-year 2026 non-GAAP loss guidance.
EQUITY | Nov 06, 2026, 02:04 PM UTC
M
Fulgent Genetics Q3 Revenue Rises 8% on Improved Collection Rates
EQUITY | Nov 05, 2026, 09:58 PM UTC
M
Fulgent Genetics Q3 2026 Earnings Call Begins
The company’s quarterly earnings call has begun.
EQUITY | Nov 05, 2026, 09:27 PM UTC
M
Fulgent Genetics reports a $13.2 million third-quarter loss
EQUITY | Nov 05, 2026, 09:07 PM UTC
M
Fulgent to Report Third-Quarter 2026 Results November 5
Fulgent said it will announce its third-quarter 2026 financial results on Thursday, November 5, 2026.
EQUITY | Oct 15, 2026, 08:11 PM UTC
H
Apple, Stryker, Coinbase And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining around 300 points on Friday. Shares of Apple Inc (NASDAQ: AAPL ) fell sharply in pre-market trading after the company posted results for th
EARNINGS | Jul 31, 2026, 12:03 PM UTC
L
FLGT (more) Earnings Notes: - Fulgent Genetics Q2 ADJ EPS $-0.58 - Expects 2026 REV $330.0-$340.0M; non-GAAP loss of about $2.22-$2.35 per s
FLGT (more) Earnings Notes: - Fulgent Genetics Q2 ADJ EPS $-0.58 - Expects 2026 REV $330.0-$340.0M; non-GAAP loss of about $2.22-$2.35 per share
EARNINGS | Jul 30, 2026, 08:20 PM UTC
L
Fulgent Genetics Lowers FY2026 Adj EPS Guidance from $(1.59) to $(2.35)-$(2.22) vs $(1.55) Est; Lowers FY2026 Sales Guidance from $350.000M
Fulgent Genetics (NASDAQ: FLGT ) lowers FY2026 Adj EPS guidance from $(1.59) to $(2.35)-$(2.22) vs $(1.55) analyst estimate. Lowers FY2026 sales outlook from $350.000 million to $330.000 million-$340.000 million vs $351.
EARNINGS | Jul 30, 2026, 08:19 PM UTC
H
MYGN -29%, RBLX -11.6%, FLGT -10.7%, VCYT -9.8%, SYK -9.5%, ALHC -8.6%, COIN -6.5%, RDDT -5.8%, GSIT -5.3%, IR -3.1% after results
MYGN -29%, RBLX -11.6%, FLGT -10.7%, VCYT -9.8%, SYK -9.5%, ALHC -8.6%, COIN -6.5%, RDDT -5.8%, GSIT -5.3%, IR -3.1% after results
EARNINGS | Jul 30, 2026, 08:15 PM UTC
L
FLGT - Fulgent Reports Second Quarter 2026 Financial Results
FLGT - Fulgent Reports Second Quarter 2026 Financial Results
EARNINGS | Jul 30, 2026, 08:10 PM UTC
L
FLGT Fulgent Genetics RESULTS: Q2, Q2 operating expenses $61.752M, Q2 Operating Income $-36.073M, Q2 pretax profit $-29.69M, Q2 gross profit
FLGT Fulgent Genetics RESULTS: Q2, Q2 operating expenses $61.752M, Q2 Operating Income $-36.073M, Q2 pretax profit $-29.69M, Q2 gross profit $25.679M, Q2 REV $85.389M, Q2 ADJ EBITDA $-17.1M
EARNINGS | Jul 30, 2026, 08:06 PM UTC